Skip to main content
AVTX
NASDAQ Life Sciences

Avalo Therapeutics Q1'26收入估计为0美元，预计每股收益为(-1.18美元) ，4月30日发布前

feedReported by Wiseek News
Sentiment info
Neutral
Importance info
7
Price
$14.711
Mkt Cap
$330.433M
52W Low
$3.39
52W High
$20.72
Market data snapshot near publication time

summarizeSummary

预计Avalo Therapeutics 将在4月30日宣布Q1'26收入为0美元，每股收益亏损(-1.18美元)。此估计为投资者预期提供了基准，表明该公司在近期内不太可能产生大量产品收入。该公司2025年的最后一份10-K报告显示，净亏损扩大，现金燃烧增加，这使得这些Q1估计与临床阶段生物技术公司一致。交易者将关注实际结果与这些估计之间的差异，以及其产品管道开发和现金跑道的任何更新，尤其是考虑到现有的7.5亿美元通用货架注册。

在该公告发布时，AVTX的交易价格为$14.71，交易所为NASDAQ，所属行业为Life Sciences，市值约为$3.3亿。 52周交易区间为$3.39至$20.72。 这则新闻被评估为中性市场情绪，重要性评分为7/10。 来源：Wiseek News。

show_chartPrice Chart

Share this article

Copied!

feed AVTX - Latest Insights

AVTX
Apr 28, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Avalo Therapeutics Secures Option to Reduce $15M Contingent Milestone Payment to $7.375M
Sentiment: Positive
View Wiseek Article
AVTX
Apr 28, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Avalo Therapeutics Buys Out $15M Milestone for $7.375M, Saving $7.6M
Sentiment: Positive
View Wiseek Article
AVTX
Apr 23, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Avalo Therapeutics Q1'26 Revenue Estimate at $0, EPS Expected at ($1.18) Ahead of April 30 Release
Sentiment: Neutral
View Wiseek Article
AVTX
Apr 10, 2026, 4:01 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Avalo Therapeutics Seeks Shareholder Approval for ESPP Extension and Board Reduction
Sentiment: Negative
View Wiseek Article
AVTX
Mar 27, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Two Directors Depart Avalo Therapeutics Board Amidst Financial Challenges
Sentiment: Negative
View Wiseek Article
AVTX
Mar 23, 2026, 7:02 AM EDT
Filing Type: 10-K
Importance Score:
8
Avalo Therapeutics Reports Widened 2025 Net Loss, Increased Cash Burn, and Significant Dilution Potential Amidst Insider Selling Plans
Sentiment: Negative
View Wiseek Article
AVTX
Mar 23, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Avalo Therapeutics Reports 2025 Financials, Extends Cash Runway into 2028, and Anticipates Key Phase 2 Data in Q2 2026
Sentiment: Positive
View Wiseek Article
AVTX
Mar 16, 2026, 4:39 PM EDT
Filing Type: 144
Importance Score:
7
Officer Files Intent to Sell $466K in Shares Following Option Exercise
Sentiment: Negative
View Wiseek Article
AVTX
Jan 12, 2026, 7:53 AM EST
Filing Type: 8-K
Importance Score:
8
Avalo Therapeutics Discloses $98M Cash, Extending Runway into 2028
Sentiment: Positive
View Wiseek Article
AVTX
Jan 08, 2026, 4:01 PM EST
Filing Type: S-3
Importance Score:
8
Avalo Therapeutics Files $750M Universal Shelf Registration, Signaling Substantial Future Dilution
Sentiment: Negative
View Wiseek Article